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reduces proliferation and migration of keratinocytes in
wounds, and hair growth was significantly reduced.6
The role of metabolic changes in keratinocyte cancers
such as BCC and squamous cell carcinoma, in addition to
associated precursor lesions, are not well characterized. To
address this deficiency, and to understand which is the pre-
dominant enzyme in tryptophan catabolism in BCC, Tina
and coworkers compared BCC biopsies and gluteal control
skin using microarray analysis to see if there was any evi-
dence of upregulated amino acid transporters and break-
down genes. They found overexpression of SLC7A5,
SLC7A7, SLC7A8 and TDO.1 They then confirmed the
increase of SLC7A5 and, for the first time in BCC, showed
an increase in SLC7A8 and TDO. This is likely to improve
tumour persistence (Fig. 1).
Although the clinical trial and drug discovery landscape
for TDO is far less advanced than for IDO1 and IDO2,2
there is now an argument to investigate inhibition of tryp-
tophan catabolism as a therapeutic avenue to treat not only
BCC but potentially keratinocyte cancer in general.
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Variants in the KRT14 gene that encodes keratin 14, are
responsible for approximately 37% of all cases of epidermoly-
sis bullosa simplex (EBS).1 EBS is characterized by skin fragility
and blistering upon minor friction. Currently, treatment of the
disease is merely symptomatic and, therefore, research into
therapeutic approaches is of great interest. Over recent years,
several therapeutic approaches have been explored, among
which are RNA-based approaches,2 such as trans-splicing.
The study by Peking and colleagues, in this issue of the
BJD,3 aimed to correct a mutation in exon 1 of KRT14 by using
a previously reported 50-trans-splicing module that replaces
exons 1–7 of the KRT14 mRNA.4 The current study aims to
elaborate on the molecular integrity of trans-splicing corrected
keratinocytes. Accordingly, the RNA trans-splicing module was
stably transduced into an EBS patient-derived keratinocyte cell
line. Subsequently, skin equivalents were generated out of
these corrected cells and grafted onto the backs of mice. These
skin equivalents revealed a stable, well-differentiated epidermis
Fig 1. A possible model for the effects of altered tryptophan
metabolism in basal cell carcinoma (BCC). The BCC expresses
increased levels of tryptophan 2,3-dioxygenase (TDO), which
increases kynurenine levels in the tissue, this has two effects. It blocks
the function of tumour-reactive T cells, which reduces tumour
immune surveillance. Also, through increased neutral amino acid
uptake it can reduce apoptosis and increase proliferation in the BCC
itself. SLC, solute carrier.
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showing the great potential of trans-splicing as a therapeutic
approach for EBS.
The major advantage of trans-splicing over many other
approaches is that one RNA trans-splicing module can be
employed to correct multiple variants in several exons, elimi-
nating the need for designing patient-specific or variant-speci-
fic therapies (Fig. 1). However, this comes at a price, as it
requires relatively large trans-splicing modules to be delivered
into the target cells.5 And this could pose a problem. Viral
delivery into cultured keratinocyte stem cells, followed by flu-
orescence activated cell sorting, subsequent generation of skin
equivalents and, finally, transplantation back into the patient
does not seem a viable approach for routine clinical applica-
tion. No doubt the preclinical results with trans-splicing have
been absolutely encouraging so far; however, the crucial factor
to determine whether or not it will eventually earn a place on
the list of genetic therapies for genetic skin conditions is
whether it will be possible to deliver the trans-splicing module
into the target cells in situ safely and efficiently. Unfortunately,
this is true for other approaches as well, and not only RNA-
based ones.6,7 But there is hope, as methods to deliver nucleic
acids such as trans-splicing modules into cells are rapidly
improving and becoming safer.8
There are high hopes of a future in which most genetic dis-
eases will be curable by virally delivered gene-editing tools
such as CRISPR (clustered regularly interspaced short palin-
dromic repeats)-guided endonucleases. CRISPR has already
proven its value in the generation of numerous disease models
and correction of diseases in vitro.9 However, it is still of great
importance that other strategies, such as trans-splicing and
other RNA-targeting therapies, are not pushed aside for this
gene-editing-future. The magic bullet of gene-editing is still
far off and complications of viral delivery, viral tropism, off--
target effects and unforeseen carcinogenicity of the CRISPR
approach and viral delivery, make RNA-based and RNA-
targeting therapeutics highly relevant. At least, for a period of
time, until gene-editing can be safely employed as it should.
Therefore, it is of great importance that reports like the one
by Peking and colleagues are published in journals like the
BJD.3 Thus, bringing to the attention of a broader range of
researchers and clinicians the numerous other therapeutic
approaches in the pipeline for genodermatoses, rather than
waiting for the magic bullet. For the heterogeneous group of
patients with epidermolysis bullosa, for whom one therapy
will not cure all, having options is good.
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Fig 1. Schematic overview of trans-splicing in the KRT14 gene. The RNA trans-splicing molecule (RTM) RTM163 comprises three major elements:
(i) a green fluorescent protein (GFP) reporter; (ii) the wild-type (WT) KRT14 cDNA exon 1–7 (purple); and (iii) an intronic binding domain
(BD) that binds to intron 7 (blue). Binding of the RTM to the endogenous pre-mRNA (grey) results into two mRNAs: the cis-spliced mutant
KRT14 mRNA and the trans-spliced WT mRNA. In this example, exon 1, a hotspot for pathogenic variants, is shown in red. In theory, pathogenic
variants located anywhere in exon 1–7 could be corrected by RTM163. In a clinical setting the GFP reporter would be removed resulting in WT
KRT14 mRNA only. In contrast to the trans-splicing approach, which is capable of correcting all variants in exon 1–7, other approaches would most
likely need the design and optimization of numerous molecules as more than 60 variants in the KRT14 have been described as causing
epidermolysis bullosa.
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This issue of the BJD includes an important study from Denmark
by Svendsen and colleagues concerning the use of topical antip-
soriatic drugs derived from a health registry.1 Information from
7743 patients during 2005–2015 revealed that topical antipsori-
atic drugs were included in 59 575 prescriptions: 31% were for
topical corticosteroids combined with calcipotriol; 6.5% for cal-
cipotriol alone; 24% for very potent topical corticosteroids;
30% for potent topical corticosteroids; and 7.2% for moderately
potent topical corticosteroids; finally, 1.6% were for topical cor-
ticosteroids combined with antimicrobials.1 The authors found
a 19% reduction in the overall prescribing of these drugs during
the 10-year study period.1
Of interest, was that a minority of these Danish patients,
just 25%, accounted for 70% of the total amount of topical
antipsoriatic drugs prescribed. Additionally, biological drugs
were used in just 6% of the patients.1 The authors speculated
that the decrease in the use of topical drugs may reflect an
increase in the use of methotrexate to control the disease.1
They also wondered if the reduced use of topical corticos-
teroids might be explained by increasing corticosteroid phobia
or even a reduction in adherence to prescribed treatment.1
In another population-based survey on topical treatments for
psoriasis, Lebwohl et al. found that most patients were under-
treated.2 Furthermore, 57% who received oral therapy and 45%
who received biological therapy discontinued topical treatment,
citing safety and/or tolerability concerns and a lack of, or loss,
of efficacy.2 This high dropout rate for topical therapies was
even more striking than in the current study by Svendsen et al.1
Patient adherence to topical psoriasis therapy is generally
low.3 The high burden of treatment and the substantial effort
required to maintain ongoing therapy frequently lead to treat-
ment fatigue.3 Thus, the decrease in the use of topical agents
reported by Svendsen et al.1 might have other, simpler explana-
tions.3–5 Furthermore, for topical dermatological products,
patients prefer and tend to be more adherent to, certain topical
vehicles based on convenience and cosmetic acceptability.3,6
Finally, Wolf et al.7 conducted a quality of life study among
Austrian patients with psoriasis: there were 1184 participants,
of whom 42.1% reported that at least 11.2% of body surface area
was affected. The authors observed that 97.2% had used topical
therapies since disease onset, but over the final 4 weeks of the
study, only 88.2% were still using topical agents.7 Overall, the
data from these three distinct studies suggests that adherence to
topical therapies is complex, and is influenced by several factors.
It is apparent from the study by Svendsen and colleagues that the
rapidly changing profile of systemic treatments for psoriasis is
having an impact on patient’s use of the most standard and tradi-
tional antipsoriasis treatments, namely topical therapies.
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